Podcasts about A1C

Send us a textMost doctors still treat insulin resistance with medication but what if the real cure starts with food?

Every 8 seconds someone dies from complications of Type 2 Diabetes... Many people accept the medical model that Type two diabetes is a progressive disease that will only worsen but along the way can be managed with medications. Type two IS progressive if you continue to do the things you are doing that got you there in the first place. But what if there were things you could do to not only prevent Type II diabetes, but even reverse it to the point where it not longer exists in those that have it? What if you didn't even have to go to the doctor for this help?That is where "Diabetes Reversal Group" comes in. Dr. Jeffrey Hockings is the founder and CEO of Diabetes Reversal Group. He is also the author of two books on metabolic health and a sought-after speaker on the future of individualized medicine. Dr. Hockings joins us today.This Episode's Blog Page: https://drhaley.com/reversing-diabetesReversing Diabetes Website: https://www.diabetesreversalgroup.net/This episode on YouTube: https://www.youtube.com/watch?v=9JeQq_kOA5gDRG on YouTube: https://www.youtube.com/@diabetesreversalgroup367DRG on Instagram: https://www.instagram.com/diabetesreversalgroup/The Study that shows unvaccinated are healthier:https://www.thegatewaypundit.com/2025/10/bombshell-vax-vs-unvax-study-finally-sees-light/ https://pubmed.ncbi.nlm.nih.gov/33266457/TIMESTAMPS:00:00 Intro Snip01:40 Introduce Dr. Jeffrey Hockings and Diabetes Reversal Group02:23 What is the difference between type 1 and type 2 diabetes?03:16 What is Mainstream Medicine?05:50 What do chiropractors think the proper use of medicine is?07:00 Why did Dr. Jeffrey Hockings get into chiropractic?09:38 What "Power Words" were spoken into Dr. Haley's life by Dr. Bob Schiffman?11:30 What "Power Words" were spoken into Dr. Jeffrey Hockings life?12:54 Are there cases of Type 2 Diabetes that are not reversable?14:22 What other conditions is diabetes causing?16:31 What are the signs of Type 2 diabetes?18:40 How does Diabetes Reversal Group work using telemedicine?20:40 How are medications like Ozempic impacting diabetes treatment?22:20 What is the patient experience like at Diabetes Reversal Group?24:00 How do they monitor their blood sugar levels?25:09 What is better, the finger stick or the CGM?29:23 Dr. Haley invites anyone wearing a CGM to participate in a case study with aloe vera30:25 What is a favorite success story?32:08 What are the blood sugar and A1C measurements to be concerned about?34:24 What are the acceptable blood sugar levels?39:40 What is Dr. Jeffrey Hockings proof that people are brainwashed?42:10 Dr. Hockings discusses a study where vaccinated and unvaccinated children were compared (link in resources).43:29 Dr. Haley explains his "pro-vaccine" approach47:03 Dr. Haley explains his brain washing research48:50 How is exercise incorporated into the program?49:40 How can exercise be bad for a diabetic?54:00 Where is the best first stop to find out more? reverseyourdiabetes.com

Hitting a metabolic wall in midlife? You're not alone — and you're not broken. In this episode, Michele Folan, midlife health coach and former diabetes industry insider, breaks down the science (and the truth) behind microdosed GLP-1 and peptide therapy for women 40+.Drawing on many years in diabetes and cardiovascular health, Michele explains how incretin hormones like GLP-1 and GIP regulate appetite, satiety, and insulin sensitivity — and why they've become game-changers for both metabolic and weight health. You'll hear:The wild origin story of GLP-1 (hint: it starts with the Gila monster)Why early GLP-1 drugs revolutionized diabetes careHow microdosing protocols now support fat loss while protecting lean muscleThe real goals: improved A1C, fasting insulin, lipids, inflammation, and energyThis isn't about shortcuts — it's about layering science-backed tools onto strong habits: ✅ Lifting heavy ✅ Eating enough protein ✅ Prioritizing recovery ✅ Partnering with trusted, physician-led telehealth and vetted compounding pharmaciesMichele also dives into other longevity peptides that support sleep, recovery, cognition, skin, and hair health — plus the role of NAD+ in cellular repair and energy.If you've been “doing everything right” and still feel stuck, this episode connects the dots between modern peptide therapy and midlife metabolism — with zero hype and total transparency.

Siquoyia Blue interviews Michelle about starting Mounjaro after a borderline diabetic A1C, the side effects she experienced (headaches, constipation, fatigue), and how she managed them. Michelle shares results—about 15 pounds lost in six weeks—advice for people who can’t exercise, thoughts on safety comparing doctor‑prescribed drugs vs. online GLP‑1s, and the importance of mental health and self‑confidence when using weight‑loss medications. Subscribe to Blu Alchemist Podcast Substack Newsletter: https://siquoyiablue.substack.com/ Podcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: https://www.blualchemistpodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Siquoyia Blue Website: https://siquoyiablue.komi.io⁠⁠⁠⁠ YouTube: @blualchemistpodcast Buy Dating Assassins Card Game: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.datingassassins.com ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want to either be a guest on or find guests for your podcast, please sign up here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.joinpodmatch.com/siquoyia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donate via Cashapp: @KingSiquoyia or Venmo: @KingShay Thanks for listening! Subscribe, Share and Follow us!

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, “Beyond Misconceptions,” and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 https://www.pharmacytimes.com/view/inhaled-insulin-demonstrates-comparable-safety-lung-function-and-efficacy-to-injectable-insulin-in-type-1-diabetes XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.   https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins   XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.     These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).   This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/   Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3   A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P

Ever feel like your blood sugar is running your life instead of the other way around? You're not alone—and you're not stuck with it forever.In this episode, I sit down with Christopher Reade, entrepreneur, technologist, and author of Beating Diabetes: How A Botched Insurance Renewal Saved My Life. Chris took his A1C from a terrifying 9.1 down to a normal 5.7 in just six months, and he's stayed medication-free for eight years. His secret? It's not some extreme diet or superhuman willpower—it's way simpler than that.Listen in to discover:How can you actually reverse type 2 diabetes without medication or extreme diets?What's the one type of fiber that can heal your pancreas and eliminate blood sugar spikes?What simple grocery store label trick makes controlling blood sugar ridiculously easy?Chris proves you don't need to be Mr. Discipline to beat diabetes. You just need the right information and a few smart habits.Ready to take control? Check out Chris's book and resources at https://www.beatingdiabetes.us/Connect with me: https://www.beginwithin.fit/podcastIf you're enjoying the Begin Within Health Show, please consider subscribing/following and leaving a 5-star review! It helps the show reach more people who could benefit from these conversations.Follow for more:⁠https://www.instagram.com/natesleger/⁠⁠https://www.tiktok.com/@natesleger⁠⁠https://www.facebook.com/groups/beginwithinfit⁠⁠https://www.youtube.com/@beginwithin3785⁠

Are your bariatric labs telling you the full story about your metabolic health? In this BariConnected episode, we're joined by Kate Foose, a passionate bariatric physician assistant, to dive deep into what post-op labs like HOMA-IR, CRP, fasting insulin, and A1C are really revealing — especially when it comes to insulin resistance, blood sugar regulation, and weight regain prevention. Whether you're a bariatric patient, healthcare professional, or someone using GLP-1s for medical weight loss, this episode is packed with science-backed insights, lifestyle strategies, and expert support from Banana Bariatrics and ProCare Health

Stop chasing labels and start changing the soil. We get honest about what creates real health—optimal function when needs are met and impediments are removed—and we map a practical path you can follow. Instead of arguing over oxalates, seed oils, or soy, we dismantle diet dogmas and return to physiology: amino acids over “protein,” plants as the mineral gateway, carbs as both fuel and structure, and why taste matters for adherence during a cleanse.We walk through a structured terrain reset: three liters of fresh juice daily built on celery, cucumber, kale, and spinach; early, dark sleep to unlock repair; digestive rest via a tighter eating window; and colon care to reopen a sluggish exit. You'll hear how the “aquarium” surrounding your cells determines everything from pain to tumors—and why removing waste and restoring flow beats symptom-hunting. We also dig into cellular voltage and practical tools like neodymium magnets for chronically stubborn injuries, plus when targeted biologics can accelerate repair once the system is primed.Weight stuck on low carb? We decode A1C and gluconeogenesis so you see why excess amino acids can show up as sugar. Thyroid labs “normal” but you feel slow? Track axillary temperature, replete iodine, and titrate support to effect, not to a reference range. Concerned about mold and “bad genes”? We cut through fear with a terrain-first plan: reduce EMF load, mobilize metals safely, rebuild the microbiome with plant fibers and fermented foods, and let sleep do the heavy lifting. For complex conditions—including pancreatic distress and liver congestion—we emphasize a three-part model: stop making the problem, target what's there without collateral damage, and wake the immune system from its stupor.If you're tired of confusion and ready for a clear, humane plan—cleanse, nourish, sleep, move, breaSend us a text Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Support the showThis episode features answers to health and cancer-related questions from Dr. Lodi's social media livestream on Jan. 19th, 2025Join Dr. Lodi's FREE Q&A livestreams every Sunday on Facebook, Instagram, and Tiktok (@drthomaslodi) and listen to the replays here.Submit your question for next Sunday's Q&A Livestream here:https://drlodi.com/live/Facebookhttps://www.facebook.com/DrThomasLodi/Instagramhttps://www.instagram.com/drthomaslodi/ Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Learn to Thrive with ADHD Podcast Welcome to the Learn to Thrive with ADHD Podcast. This is the show for you if you're... Listen on: Apple Podcasts Spotify Join Dr. Lodi's informative FREE Livestreams...

A Fortune 250 company in Des Moines, Iowa transformed employee health through a whole-food, plant-based lifestyle.    Discover how Gretchen Barris teamed up with PCRM and Dr. Jim Loomis to launch a 16-week wellness program at Principal Financial that helped 240 participants dramatically lower cholesterol, reverse prediabetes, lose weight, and boost energy — all for just $108 per person.   Chuck Carroll sits down with Jean McGinnis and participants like Malcolm & Suzanne Showalter who conquered migraines, reversed heart disease risk, and experienced newfound vitality. Learn how this evidence-based approach from the Barnard Medical Center and PCRM is revolutionizing corporate wellness — even in the heart of the Midwest!   What You'll Learn in This Episode - How a Fortune 250 company implemented a plant-based program on a small budget - The average 23% LDL reduction and 18% A1C improvement among participants - Why employees reported better sleep, focus, and mental health - The difference between “health care” and “sick care,” explained by Dr. Loomis - How to bring programs like this to your own workplace  

This groundbreaking episode unveils Stanford Professor Michael Snyder's revolutionary research published in Nature Biomedical Engineering revealing that type 2 diabetes and insulin resistance aren't single diseases but four distinct metabolic subtypes requiring personalized fasting and nutrition strategies. The hosts decode how muscle insulin resistance demands early time-restricted eating with 18:6 or OMAD plus resistance training, beta cell dysfunction requires gentle 16:8 fasting while avoiding extended fasts to prevent pancreatic burnout, impaired incretin effect needs pre-meal walking with fermented foods to enhance gut hormone signaling, and liver glucose dysregulation necessitates 30-36 hour fasts weekly to reset hepatic insulin resistance and stop the liver's continuous glucose output. Dr. Scott and Tommy explain why A1C measurements provide almost no insight into underlying mechanisms, with individuals showing normal A1C yet severe insulin resistance while others display pre-diabetic A1C with preserved insulin sensitivity, making traditional one-size-fits-all weight loss recommendations fundamentally flawed. The episode introduces at-home oral glucose tolerance testing to decode personal glucose curves and identify specific pathology, while emphasizing foundational recommendations—early meals, resistance training, post-meal walks, protein prioritization, sleep protection, and stress management—move the needle for most people regardless of subtype, with personalized optimization becoming critical for those stuck despite consistent effort. ⁠⁠⁠⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Resources and Downloads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Partner Links: Get your⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠25% off a Keto-Mojo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fasting For Life Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://www.nature.com/articles/s41551-024-01311-6

What if your menstrual cycle, cholesterol, and even your VO₂ max could predict your future health? Most women aren't tracking what really matters—until it's too late.Michelle MacDonald welcomes Dr. Amy Louis-Bayliss, a MD and women's preventive health expert, to uncover the six key metrics that can radically improve how women age. With decades of experience in emergency medicine and specialized training in menopause, Dr. Amy breaks down complex topics like cholesterol, A1C, body composition, VO₂ max, blood pressure, and cycle health in a way that is both actionable and empowering. She shares how understanding these markers, not just your weight, can shift you from reactive care to proactive, personalized health optimization. Favorite Moments:2:33 The Six Tests Every Woman Over 40 Needs to Take11:27 Why Women Shouldn't Fear Cholesterol Meds—Or Estrogen21:50 Think You Feel Fine? Your Blood Pressure Might Say Otherwise34:56 The Shocking Truth About Thin Women and Muscle Loss"You can feel good, but that's not the same as measuring." – Dr. Amy Louis-BaylissGUEST: DR. AMY LOUIS-BAYLISS BHSc, MD, FRCP©, CEO LUME WOMEN + HEALTHWebsite | Contact | LinkedIn | Instagram | NewsletterFull Guest Bio: Dr. Amy Louis-Bayliss has been an MD for almost 20 years, spending most of her career as an emergency medicine specialist with two additional years of training as a menopause specialist in Hamilton and Oakville. Dr. Louis-Bayliss is an advocate for women's healthy aging – her interest in menopause and healthy aging stems from years of treating and managing disease in the ER once it was already “too late”. Amy sits on the advisory board for the National Menopause Show. She is passionate about educating women to build self-agency when it comes to disease-prevention.CONNECT WITH MICHELLEWebsite | Instagram | YouTube | Facebook | XFull Michelle Bio: Michelle MacDonald is the creator of the FITNESS MODEL BLUEPRINT™ and host of the Stronger By Design™ podcast. Known globally for her transformation programs, Michelle empowers women to redefine aging through evidence-based strength training, nutrition, and mindset practices. Since 2012, she has coached thousands of women online, leveraging her expertise as a Physique Champion and ISSA Strength and Conditioning Specialist. She co-founded Tulum Strength Club and established The Wonder Women (TWW), inspiring countless transformations including her mother, Joan MacDonald (Train With Joan™). Michelle continues to lead the charge in women's fitness, launching the Stronger by Design™ fitness app in fall 2024.Where to Watch/Listen:WebsiteApple PodcastsSpotifyYouTube

Episode 2708 - Vinnie Tortorich and Chris Shaffer welcome call-in guests to discuss motivation sparked by one foot in the grave, and pushback from family. https://vinnietortorich.com/2025/10/one-foot-in-the-grave-episode-2708 PLEASE SUPPORT OUR SPONSORS   YOU CAN WATCH THIS EPISODE ON YOUTUBE - One Foot In The Grave Social media concerns. (2:00) Vinnie had an experience over X years ago regarding American Girl dolls. (4:00) There was a miscommunication, and he had to stay up all night to correct the mistake. Vinnie had only suggested making a fitness-themed doll. Eric is the first guest caller. (18:00) He's lost some weight with NSNG® and has spine issues. Eric is looking forward to Vinnie's workout videos that will be released in the NSNG® VIP group. They discuss issues Eric has had dealing with cholesterol and his doctor. (30:00) The ratio between HDL and Triglycerides is a better indicator of heart health. Carbohydrates really don't help you build muscle; 5g of creatine is better. (43:00) Some sports or competitions can be fueled with a small sugar trickle because blood glycogen gets used up so quickly. Examples would be kickboxing or boxing. Family Pushback Scott is the next guest. He has lost 325 pounds after starting NSNG® after hearing Vinnie on Mike Rowe's podcast. Why does it take people to be told they have one foot in the grave before it sparks change? (48:00) Scott's wife has lost over 100 pounds, and his son has lost 90 pounds! Scott has reversed COPD and congestive heart failure symptoms. (55:00) Hobbies are important to help your mind explore. (1:01:00) Scott has had family blowback about his new healthy lifestyle. A family member reported him to Adult Protective Services! (1:04:00) He had to go through three months of investigation. The accusation was abuse because of the change in eating and daily walks. Scott's wife has lowered her A1C and gotten off of insulin. (1:11:00) Vinnie shares a story about an NSNG® follower named Robert Stanton. (1:19:00) If you are interested in the NSNG® VIP group, it will be reopening soon. But you can get on the wait list - More News If you are interested in the NSNG® VIP group, it will be reopening soon. But you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.    PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

Alzheimer's and dementia aren't just a matter of age or genetics. Increasing evidence shows that metabolic health—particularly insulin resistance—plays a key role in cognitive decline.In this episode of A Whole New Level, neurologist and bestselling author Dr. David Perlmutter joins Mike Haney to explore the links between brain health and metabolism. They discuss the role of insulin resistance and inflammation in Alzheimer's disease, the biomarkers that can reveal risk decades before symptoms, and how lifestyle interventions can dramatically change your trajectory.Topics include:Key biomarkers for assessing brain health: fasting insulin, A1C, homocysteineWhy targeting inflammation may matter more than targeting amyloid plaquesThe promise and limitations of GLP-1 medications for dementia and Parkinson'sPractical steps you can take now to protect long-term cognitive functionSign Up to Get Your Free Ultimate Guide to Glucose: https://levels.link/wnl

In this episode of the HealthspanMD Podcast, Dr. Robert Todd Hurst, MD, FACC, FASE sits down with Patty and Rick Rife to unpack their powerful journey through proactive, personalized care. After years of strict vegan eating, they were shocked to discover early signs of heart disease, prediabetes, and rising blood pressure. What followed was a complete transformation driven by advanced testing, continuous glucose monitoring, and a tailored plan that actually worked for their bodies.   In this episode of the HealthspanMD Podcast, Dr. Robert Todd Hurst, MD, FACC, FASE sits down with Patty and Rick Rife to unpack their powerful journey through proactive, personalized care. After years of strict vegan eating, they were shocked to discover early signs of heart disease, prediabetes, and rising blood pressure. What followed was a complete transformation driven by advanced testing, continuous glucose monitoring, and a tailored plan that actually worked for their bodies.   They share how switching to a low-carb, high-protein diet led to dramatic improvements in energy, labs, and overall health, and why health is always a team effort. Whether you're feeling stuck with your current plan or wondering if your numbers tell the whole story, this episode is a must-listen.   Patty and Rick Rife are a health-conscious couple who came to HealthspanMD looking for clarity, not just checkups. After four years on a strict plant-based diet, Rick's elevated calcium score, insulin resistance, and surprising lab results sparked a major shift. Under the guidance of Dr. Robert Todd Hurst, MD, FACC, FASE, they adopted a more personalized, results-driven approach and reversed their risk trajectory in weeks.    Key Timestamps 00:00 – Meet Patty and Rick Rife + why they came to HealthspanMD 02:00 – Going vegan for heart health: expectations vs reality 04:30 – Early signs of arterial plaque and metabolic dysfunction 06:00 – When “healthy” isn't enough: lab results that shocked them 08:15 – From vegan to low-carb: making the dietary pivot 11:00 – Dramatic changes in A1C, triglycerides, and insulin in 5 weeks 13:45 – The power of CGMs for personalized feedback 15:30 – “Healthy” foods that spiked blood sugar, and what didn't 18:30 – How food order, stress, and walking affect glucose response 21:00 – Why one diet does not fit all 24:00 – Repatha, medication strategy, and reversing artery disease 27:00 – Mindset shifts, confidence, and redefining health together 30:00 – Health as a team sport and what's next for the Rifes This information is for educational purposes only and is not medical advice. Don't make any decisions about your medical treatment without first talking to your doctor. *Connect* *with* *HealthspanMD* :

Prof. Joan Buckley and Pandora Groth learn about Type 2 Diabetes - how it's diagnosed, treated, and managed. And don't worry — this show is sugar-free... but packed with plenty of sweet info!  They speak with Dr. Daniel J. Cox, a Professor in the Departments of Psychiatry and Internal Medicine, at the University of Virginia Health Sciences Center.

Are you stuck trying diet after diet… only to see the scale bounce back?⁠

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

Dr. Lori Bouchard, a naturopathic doctor focused on cancer care, shares why more women in their 30s–40s are being diagnosed at late stages - even when they “feel fine” - and exactly how to get ahead of it with annual baselines, smart labs (insulin, A1c, hs-CRP/ESR, homocysteine), detox strategies, fasting, stress regulation, and heat-based therapies. If you're a proactive, health-curious woman, especially a busy mom, who wants a clear, science-backed game plan to catch cancer risk early with smart labs, stress resets, detox, fasting, and sauna, this episode is your playbook. WE TALK ABOUT:  06:00 – The shocking shift in cancer demographics (younger women, later stages) 07:20 – First steps when you're overwhelmed by a new diagnosis 10:45 – Key biomarkers for cancer detection 19:50 – Nervous system as prevention - breathwork, gratitude, grounding 22:40 – How to do a personal health audit 23:40 – “Detox is BS?” Testing reveals what the body still holds onto 26:55 – Sauna & hyperthermia for detox and tumor microenvironments 30:50 – Proactive health strategies for cancer prevention 36:50 – Perfectionism, type-A patterns, and why rest is medicine 44:15 – Teaching kids real-world food literacy and boundaries SPONSORS: Reset stress on demand with Pulsetto (code: BIOHACKINGBRITTANY) - a neck-worn vagus-nerve stim that calms stress in ~4 minutes so you sleep better and feel calmer. Join me in Costa Rica for Optimize Her, a 5-night luxury women's retreat in Costa Rica with yoga, healing rituals, and biohacking workshops—only 12 spots available. RESOURCES: Trying to conceive? Join my Baby Steps Course to optimize your fertility with biohacking. Free gift: Download my hormone-balancing, fertility-boosting chocolate recipe. Explore my luxury retreats and wellness events for women. Shop my faves: Check out my Amazon storefront for wellness essentials. Dr. Lori Bouchard's website and Instagram LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

‣ Book Your COMPLEMENTARY CONSULATION and CALORIE CALCULATION call:- how much & what to eat, exercise & lifestyle recommendations, and specific resources to support you on your journey

Episode #225 In this powerful Member Transformation episode, Coach Terri sits down with Kirsten Hopkinson to explore how fasting has become more than just a weight-loss tool—it's reshaped her identity, health, and outlook on life. Kirsten shares how she's lost 50 pounds since joining The Fasting Method, lowered her A1C from pre-diabetic to healthy range, and discovered the deeper “why” driving her journey. From morning walks and mindset shifts to overcoming old habits and finding strength in community support, Kirsten's story is about creating sustainable change and living with purpose. If you're ready to move beyond diets and into a lifestyle of self-care, resilience, and transformation, this conversation will inspire you to take the next step.    ✨ Ready to start your own transformation? Join The Fasting Method Community today and get the tools, coaching, and support you need to create lasting change. https://www.thefastingmethod.com/community/   Transcripts of all episodes are available on the Podcast page at www.thefastingmethod.com   Book a complimentary 15-minute coaching intake assessment with one of the TFM coaches https://www.thefastingmethod.com/coaching/   Connect With Us Instagram: https://www.instagram.com/fastingmethod/ Facebook Page: https://www.facebook.com/TheFastingMethod Join our FREE Facebook Group: https://bit.ly/TFMNetwork   Summary Timestamps 00:00 Introduction 01:22 Starting the Journey 02:45 What's Different This Time 04:25 Finding a North Star 07:11 Power of Community 11:09 Struggles & Support 15:47 Beyond Fasting 17:35 Letting Go of Numbing Tools 19:13 Feeling Big Emotions 21:46 Transformation Beyond the Scale 23:19 Advice for Beginners 27:31 Picturing the Future 28:34 Redefining Self-Care 29:16 Closing Thoughts     Disclaimer This podcast is for educational purposes only and is not a substitute for professional care by a doctor or other qualified medical professional. You should always speak with your physician or other healthcare professional before doing any fasting, changing your diet, taking or adjusting any medication or supplements, or adopting any treatment for a health problem. The use of any other products or services purchased by you as a result of this podcast does not create a healthcare provider-patient relationship between you and any of the experts affiliated with this podcast. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Fit Mother Project Podcast number 166 introduces us to Dr. Melissa Mahan. A 59-year-old grandmother of six, higher-ed leader, and certified professional coach from San Antonio who refused to let family history dictate her future. After a routine checkup in early 2024 revealed an A1C of 6.6 with high cholesterol and blood pressure, she chose a structured, natural path over medication—and found the Fit Mother Project. What followed was a systems-driven transformation built on consistent action, community support, and faith. Within months, Melissa dropped her A1C to ~6.0, normalized her blood pressure, improved her lipid ratios, and lost ~35 pounds—largely by dialing in “protein first,” lifting consistently, and stacking simple habits like morning sunlight walks. She also learned powerful glucose-management strategies through a CGM, discovering how pairing protein/fiber (and avoiding “spike-on-a-spike” combos like soda before pizza) dramatically changed her numbers. Melissa shares the tweaks that mattered (e.g., swapping coconut milk for almond milk in shakes and adding psyllium husk), along with her mantra of the “relentless return”—not perfection, but always coming back to the next right action. She describes how Fit Mother retreats, small-group coaching, and the in-app sisterhood reinforced mindset shifts, helped her navigate menopause challenges, and kept her on track during celebration-heavy seasons. Now, just shy of 60, Melissa is training for senior-level cycling events and planning a 500-mile Camino de Santiago ride in Spain—proof that health creates possibilities. Her challenge to listeners: dare to dream, set a meaningful goal, and finish this year strong.Key Takeaways:A1C 6.6 → ~6.0; BP/lipids trending normal~35 pounds down; energy and mood up“Protein first” meals; stronger satiety, fewer cravingsCGM insights; smarter food order and pairingSkip soda-before-pizza; avoid “spike on a spike”Fiber + protein before carbs; steadier glucoseAlmond milk swap; lower sugar, cleaner shakesPsyllium add-in; soluble fiber, better fullnessMorning sunlight + 20–30 min walk stackStrength training 2–4x/week; progressive overloadPower-meter cycling; targeted endurance gainsRetreats + small groups; consistent accountabilityMenopause-aware tweaks; sleep and stress prioritized“Relentless return” mindset; progress over perfectionBig goal: 500-mile Camino; senior cycling eventsWant To Change Your Life? Check Out Foundations!Foundations is a simple, sustainable, and specific weight loss program designed especially for busy women over 40. With short metabolic training workouts, an easy-to-follow meal plan, and an accountability team there for you every step of the way, Foundations can help you lose weight, regain energy and vitality, and live life to the fullest. Click here to see everything you get when you join FM30X, subscribe to our YouTube Channel, check out our blog, and follow us on Instagram, TikTok, Facebook,

Get My Book On Amazon: https://a.co/d/avbaV48DownloadThe Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/Book A Call With Me: https://hunterwilliamscall.carrd.co/Supplement Sources: https://hunterwilliamssupplements.carrd.co/Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DYSocials:Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/In today's video I unpack amlexanox—an old anti-inflammatory/allergy drug with surprising metabolic effects. I share my first encounter with it in the research-chem world, what I noticed subjectively, and then dive into mechanisms (IKKε/TBK1 inhibition, catecholamine resensitization, beige fat), rodent data, the Phase 2 human trial (150 mg/day), safety, dosing, who seems to respond best, and how I'm stacking it inside Bio Ignite. If your goal is fat loss with stubborn adipose inflammation, this is worth understanding.0:00 - Welcome + what today's video covers0:28 - How I first found “AM Lox” browsing catalogs1:06 - Cycling off SLU-PP-332 and first personal trial1:40 - Noticing dryness/ab definition; early under-dosing2:12 - 2025 “sugar diet” + hunting for FGF21 boosters2:40 - Finding data that amlexanox increases FGF213:02 - Literature dosage (100–150 mg) vs my early dose3:38 - Why I think it's a useful fat-loss rotation tool4:24 - Channel/hosting update + where to find my videos5:08 - Slides start: what amlexanox is/was used for6:00 - Core mechanism: IKKε/TBK1 → PDE3B → cAMP resistance7:16 - IL-6→STAT3 hepatic signaling + beigeing via FGF218:30 - Big-picture benefits: inflammation, insulin sensitivity, glycemia10:32 - Human data: Phase 2 trial (150 mg/day x 12 weeks)11:10 - Modest/variable weight change; who improved most12:37 - Practical takeaways: glycemia, liver fat, insulin sensitivity14:12 - Dosing in practice (50 mg caps, TID = 150 mg/day)15:12 - Responder phenotype: high adipose inflammation16:00 - Who benefits most + variability at similar body fat17:56 - Study roll-up and mechanism recap18:52 - Final thoughts, use-cases, and product note (Bio Ignite)19:54 - Thank you + where to grab the peptide cheat sheetWhat You'll LearnWhy amlexanox can “release the brakes” on fat-burning by inhibiting IKKε/TBK1 and restoring cAMP/catecholamine responsiveness.How it raises IL-6 transiently in adipose, activates STAT3 in the liver, suppresses gluconeogenesis, and increases FGF21 to promote beige fat programs.The mouse vs. human gap: robust fat loss in mice; in humans, clearer improvements in A1c, fructosamine, liver fat, insulin sensitivity—especially when adipose inflammation is high.Dosing used in the Phase 2 trial: 50 mg TID (total 150 mg/day) for 12 weeks.Safety snapshot: no serious AEs attributed to amlexanox in metabolic trials; most common was a transient rash.Timestamps (exact to the transcript)What you'll learn

The word “cure” gets thrown around a lot when it comes to type 2 diabetes, but what's the real story? In this episode, Dr. Jedha sets the record straight. You'll learn why “remission” is the accurate medical term, what it actually means, and how thousands of people are living free of diabetes medications with normal A1c levels, often in just a few months, using nothing more than food and lifestyle.We'll explore the powerful shift happening in diabetes care, backed by decades of data and firsthand member stories. You'll hear how people have gone from insulin and multiple medications to none at all, and discover what the research says about deprescribing, even in older adults. Plus, we flip the narrative to uncover the truth: maybe the problem isn't you… maybe it's the system that never showed you another path. If you've been led to believe that long-term medication is your only option, this episode is a must-listen and will open your eyes to hope, science, and reclaiming your power!For show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

Type 2 diabetes is one of the most common chronic conditions in the U.S., but it doesn't have to define or limit your life. In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus—two endocrinologists with decades of experience—break down practical strategies for living well with type 2. From the latest medications and tools to everyday lifestyle choices, they highlight what really makes a difference in the long run. Their goal? To show you that type 2 diabetes is not only manageable but that taking control can actually improve your health and quality of life.Get Educated About What's Happening in Your Body: Understanding insulin resistance, metabolic syndrome, and why type 2 diabetes is more than just “high blood sugar.”Know Your Numbers: The key benchmarks for A1c, blood sugar, cholesterol, and blood pressure—and why even small improvements matter.Build the Right Care Team: How to find and work with providers who can guide you through treatment options and keep you on track.Food and Drink That Work for You: Why portion control, balance, and smart substitutions matter more than strict diets or deprivation.Move Your Body (Without Overthinking Exercise): How realistic activity goals—walking, stretching, or even gardening—can improve insulin sensitivity and overall health.The Medications Changing the Game: Why GLP-1s, SGLT2 inhibitors, and CGMs are considered life-changing tools in type 2 diabetes care—and what you should know about them.And That's Just the Start…: From mental health to long-term complication prevention, there are even more strategies in this episode to help you thrive with type 2 diabetes. ★ Support this podcast ★

JB White comes in fired up on this episode of the RattlerGator Report, celebrating the long-awaited indictment of James Comey and what it signals about the floodgates finally opening. He vents about the delays in his own hip surgery thanks to high A1C numbers, then quickly turns back to politics, walking listeners through Trump's tossed RICO lawsuit and why it deserves reinstatement on appeal. With sharp commentary, JB explains why keeping insiders close exposes networks, why patience and perseverance are essential, and how Trump's team has been playing the long game. From surveillance of Comey's family to the role of partisan judges, the conversation brims with urgency, faith, and humor. JB also drops his signature mantra, patience, preparation, perseverance, flexibility, resiliency, while weaving in reflections on Ben Carson, Obama, Charlie Kirk, and the cultural battles shaping America. With laughs, candor, and conviction, this episode feels like both a victory lap and a rallying cry: nothing can stop what is coming.

In this episode of Intermittent Fasting Stories, Gin talks to Triple J from Anniston, AL.Are you ready to take your intermittent fasting lifestyle to the next level? There's nothing better than community to help with that. In the Delay, Don't Deny community we all embrace the clean fast, and there's just the right support for you as you live your intermittent fasting lifestyle. You can connect directly with Gin in the Ask Gin group, and she will answer all of your questions personally. If you're new to intermittent fasting or recommitting to the IF lifestyle, join the 28-Day FAST Start group. After your fast start, join us for support in The 1st Year group. Need tips for long term maintenance? We have a place for that! There are many more useful spaces beyond these, and you can interact in as many as you like. Visit ginstephens.com/community to join us. An annual membership costs just over a dollar a week when you do the math. If you aren't ready to fully commit for a year, join for a month and you can cancel at any time. If you know you'll want to stay forever, we also have a lifetime membership option available. IF is free. You don't need to join our community to fast. But if you're looking for support from a community of like-minded IFers, we are here for you at ginstephens.com/community. Triple J works for the federal government, he's a minister at his church, and he wears a lot of other hats, as well. Triple J shares his inspiring journey of health transformation through intermittent fasting and lifestyle changes. Starting from a background of spiritual fasting, Triple J faced significant health challenges, including type two diabetes and a high A1C level. Through a combination of keto and intermittent fasting, he successfully lowered his A1C and ultimately came off all medications and put his diabetes into remission. He discusses the importance of clean fasting, listening to his body, and adapting his diet to maintain his health. The conversation also touches on his heart surgery and the ongoing journey of recovery and family legacy. At one point in his journey, Triple J experienced some self-sabotage, and he needed to work through that challenge. He explains how community support has been instrumental in achieving health goals. He emphases the power of mindset and having patience in the process. Triple J highlights the significance of sharing experiences within a supportive community and offers encouragement for those starting their own health journeys. As the episode ends, Triple J tells new intermittent fasters to be patient—with both yourself, and the process. Don't try to do everything all at once, and know that good things take time and can't be rushed.Get Gin's books at: https://www.ginstephens.com/get-the-books.html. Good news! The second edition of Delay, Don't Deny is now available in ebook, paperback, hardback, and audiobook. This is the book that you'll want to start with or share with others, as it is a simple introduction to IF. It's been updated to include the clean fast, an easier to understand and more thorough description of ADF and all of your ADF options, and an all new success stories section. When shopping, make sure to get the second edition, which has a 2024 publication date. The audiobook for the second edition is available now! Join Gin's community! Go to: ginstephens.com/communityDo you enjoy Intermittent Fasting Stories? You'll probably also like Gin's other podcast with cohost Sheri Bullock: Fast. Feast. Repeat. Intermittent Fasting for Life. Find it wherever you listen to podcasts. Share your intermittent fasting stories with Gin: gin@intermittentfastingstories.comVisit Gin's website at: ginstephens.com Check out Gin's Favorite Things at http://www.ginstephens.com/gins-favorite-things.htmlSubscribe to Gin's YouTube Channel! https://www.youtube.com/channel/UC_frGNiTEoJ88rZOwvuG2CASee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to Indulgence Gospel After Dark!We are Corinne Fay and Virginia Sole-Smith. These episodes are usually just for our Extra Butter membership tier — but today we're releasing this one to the whole list. So enjoy! (And if you love it, go paid so you don't miss the next one!) Episode 212 TranscriptCorinneToday is a family meeting episode. We're catching up on summer breaks, back to school, and a whole bunch of diet culture news stories that we've been wanting to discuss with you all.VirginiaWe're also remembering how to make a podcast, because we haven't recorded together in like six weeks. And it didn't start off great. But I think we're ready to go now.CorinneSomeone definitely said, “What day is it?”VirginiaIt's hard coming out of summer mode. I don't know if you feel that because you don't have kids, during back to school, but it is a culture shift.CorinneI don't think I feel the back to school thing as much, but I'm still in Maine, and it's actively fall. It's actively getting cold, and I'm just like, what is happening? I feel this pressure to do something, but I'm not sure what? Hibernate?Virginia“Should I buy a notebook? Should I be wearing fleece? I could go either way.” I don't know. It's weird. It is the start of fall. So we are moving into fall mindset. But like, don't rush me, you know? The dahlias bloom till first frost. That's my summer.CorinneSummer is so brief.VirginiaI'm having a lot of clothing feelings right now. I am not in a good place getting dressed, and it is for sure weather related, shoulder season-related. I'm in my annual conundrum of when do the Birkenstocks go away? When must our toes be covered for polite society? Am I showing arms? I just I don't even know how to get dressed. I hate all my clothes. Everything's terrible.CorinneI think this is part of what I'm feeling. I don't have enough warm clothes and I also don't want to buy another pair of sweatpants.VirginiaAnd you're traveling. So you're like, “I have warm clothes at home.” Didn't bring them because you didn't understand, even though you grew up in Maine and should remember that fall starts quite early there.CorinneI need to get it tattooed on my body. Bring a sweater, bring sweatpants.VirginiaWell, to be fair for this Maine trip, you were really focused on your sister's wedding. You had your nephew. You've had a lot going on.CorinneI was very focused on August, and really not thinking about September.VirginiaWill we even exist after? I mean, that's how it always is when you're gearing up for a big event, the post-event doesn't exist.And I don't know if you do the thing where you're like, well, I can deal with that after the big event. And then suddenly it's after the big event. You're like, well, now there's 47 things I need to deal with.CorinneI absolutely do that. Now I'm like, wait. How and when do I get back to New Mexico? Am I going back to New Mexico ever? In which case maybe I do need to buy sweatpants?VirginiaIt's so hard. Even without a wedding —I feel like all summer, because I have pretty skeleton childcare and I'm wanting to take time off, and it's a privilege that our job allows some flexibility like that, so when I get requests to, like, do a podcast, do a special thing. I'm like, “Talk to me in September. I can't do it this summer. Summer mode Virginia can't do anything extra!” And now I've just spent the week saying no to lots of things, because September me can't do it either. That was folly. I should have just said no the first time!That's one of those life lessons I'm always relearning that's really funny. If it's not an instant yes, it's a no. And I so often fall into the trap of it's not an instant yes, so let me kick that can down the curb a little bit, and then then I feel ruder because they come back and I'm like, no, I'm sorry. Actually, we were never going to do that.CorinneAs someone who's been on the other side of that where, like, I'll reach out to someone for the Style Questionnaire, and they'll be like, “Oh, can you ask me in two months?” And then when I reach out in two months, and they're like, “No.”VirginiaTotally. I'm on the other side of it all the time when we're booking podcast guests. So I'm completely aware of how shitty it feels. So I have a resolution. Summer Virginia just has to say no to things and not push it to Fall Virginia. Everyone hold me accountable next summer, because I'm so sorry to everybody I've said no to this week, but September is a real intense parenting month. There are just a lot of moving parts.I get 62 emails a day from the school. The middle school just announced back to school night will be tomorrow. They told us yesterday! One cool thing is, my older kid is in seventh grade now, so I no longer have to scramble for babysitters, which is a real achievement unlocked. Although she's going to realize at some point that she should increase her rates with me.CorinneOh, you pay her!VirginiaFor stuff where I'm going to be out of the house and need her to put her sister to bed. It's one thing, if I'm like, “I'm going to the store, you guys don't want to come.” Fine. You can doodle around at home. And it's not even really babysitting. She's going to ignore her the whole time. But I'm going to be out from 6 to 8pm tomorrow night. I need her to actually make sure her younger sibling gets in pajamas and brushes teeth and, moves towards bed. I'm not expecting them to be in bed when I get home, but I would like them to not be nowhere close.CorinneThat's really sweet.VirginiaPlus we have some big stuff in the works for both Burnt Toast and Big Undies, which we cannot discuss just yet. Yes, I am actively teasing it for you all.CorinneYou're going to bring that up now?! I feel like we should mention it at the end.VirginiaI think we can mention it whenever we feel like? I think they're probably like, “Why are they both doing reader surveys? What's going on?” And we can't say yet, but there's something going on, and it's also requiring a lot of our time and attention.CorinneWe're really busy. But I think it's going to be really good, and everyone's going to love it.VirginiaIn the meantime, though: What are we wearing? Real talk, what are we wearing to get through this weird it's not summer, it's not fall, it's some hybrid state. Are you still wearing open toed shoes? Sandals?CorinneNo, I'm not.VirginiaOkay. Should I stop, too?CorinneI mean, I'm only not because I'm cold. It depends on if you're cold. I also think now is kind of the perfect time for socks with sandals.VirginiaMost of my sandals are something between my toes style. CorinneOh, I was thinking, like, socks with Birkenstocks.VirginiaAh! I do have some of the two strap Birkenstocks, and I don't tend to wear them a lot in summer. Maybe I should experiment!CorinneI feel like, when you wear socks with the two strap Birkenstocks, they become really cozy.VirginiaI don't wear them a lot in summer because I don't have particularly wide feet, and they're a little wide on me. But the sock would solve for that! And they would be cozy… all right, I'm going to experiment with this, as part of my shoulder season style.CorinneI'm still figuring out my fall must haves, which is one of my favorite topics. Although I will say I feel like this year I've seen a lot of people posting like, “I don't want to hear about back to school, or I don't want to hear about fall fashion.”VirginiaI have terrible news for people about this podcast. CorinneI feel it's very light hearted. It could be literally anything like, who cares? We are entering fall, so…VirginiaTime is passing.CorinneI am getting cold. I do want to put on socks with my sandals and sweatshirts.VirginiaTrigger warning for anyone who is not available for a fall fashion conversation.CorinneMaybe by the time this comes out, people will be ready.I know this is like florals for spring, but I'm feeling for fall… brown pants.VirginiaWait, what? You're blowing my mind? You've been feeling brown for a little while. CorinneBrown has been ramping up. I'm wearing brown pants right now.VirginiaIs it one of your colors, as a true spring?CorinneWell, I do think there are definitely some camels. And I think brown is preferable to black. So I'm thinking brown pants instead of black pants.VirginiaOh, I don't even know what I'm thinking about pants. I'm thinking frustration with pants. I have my one pair of jeans that I reliably wear. I think I need to order another pair in case they stop making them. I'm at a scarcity mindset point with those Gap jeans. I mean, they aren't going to stop making them. They've had them for years, but I just feel like I need an insurance policy.CorinneDo you fit other Gap pants, or just the jeans?VirginiaI only buy that one pair of jeans. I mean, I generally try not to shop at the Gap because they do not have a plus size section.CorinneBut they do have some really cute stuff.VirginiaIt's gross though! Make it bigger.CorinneIf it fits you, maybe you should buy it.VirginiaCorinne is like, “Or counterpoint, don't take a stand.”CorinneI'm always sending links to my straight-size sister for stuff at the Gap that I think she should buy.VirginiaThey do have some really cute stuff, but it infuriates me that Old Navy can make plus sizes, and Gap cannot, and Banana Republic really cannot. It's just like, hello, class system, capitalism. It's so revolting.CorinneOh, my God. Do you know what else I'm feeling outraged about? I went thrift shopping here a couple weeks ago, and I found some vintage Land's End that was in sizes that they don't make anymore.VirginiaWow, that's rude.CorinneIt was a 4X! So they used to be way more 26/28 or 28/30. So they also, at some point, kind of cut back.VirginiaThey do, at least legitimately have a section called plus size, though.CorinneThey do, but it clearly used to be bigger.VirginiaNo, no, no. I'm not saying it's great. I am wearing my favorite joggers a lot, because I think I'm really resisting the shift back to hard pants.CorinneHow do you feel about trousers, like a pleated trouser kind of pant?VirginiaIs that comfortable for working from home? A pleated trouser?CorinneWell, I feel like they're comfortable because they're kind of baggy but narrower at the bottom, you know?VirginiaI do love a tapered ankle. I also unpaused my Nuuly. And I did get a blue corduroy pair of pants from them that it hasn't been quite cold enough to wear because shoulder seasons. Corduroy, to me is like a real like we are fully in cold weather fabric. And when it's 50 in the morning, but 75 by lunchtime, am I going to be hot in corduroys? I guess I should just start wearing them and see.CorinneAre they jeans style? VirginiaThey're slightly cropped so that's another reason to wear them now, while I can still have bare ankles. They're slightly cropped and slightly flared, and they're like a royal blue corduroy.They're Pilcro, which is an Anthropologie brand and I know we feel gross about Anthropologie. But when it comes to pants, I think Corinne is saying we can't have moral stances because pants are so hard to find. Other things, yes.CorinneIt's just hard.VirginiaI'm not excited about clothes right now. I want to feel more excited. Maybe I need to think about what my fall must haves are. Maybe I need to make a pin board or something.CorinneI think that's a good idea. Is there anything you're feeling excited about? I remember the last episode you were talking about those Imbodhi pants.VirginiaOh yeah. They've really become lounge around the house pants, and they're great, but they're very thin. Imbodhi feels like a brand you could not wear once it gets cold.Although, the jumpsuit I have from them in periwinkle—which does feel like a very summery color to me—I also got black. And over the summer it felt a little too black jumpsuit. It felt like too formal or something. But I've been enjoying it as a transition piece. I am still wearing it with sandals. I think it would look cute with maybe my Veja sneakers, though, and then layering over my denim shirt from Universal Standard, like open over it.I'm glad we're talking about this, because that's what I'm going to wear to back to school night tomorrow night, which is a high pressure dressing occasion.CorinneI can see that.VirginiaYou don't want to look like you tried too hard, but you also don't want to look like you came in pajamas. Lots of yoga moms, a lot of pressure. Okay, I'm going to wear that black jumpsuit. I'm glad we talked about that. That's been a good transition piece.CorinneYeah, okay, well, speaking of transitions, I want to ask you about something else. Are you familiar with the Bechdel Test?VirginiaYes.CorinneDon't you think we should have a Bechdel test for anti-fatness? And/or diets? Like, does this piece of culture have a fat character who's not the bad guy, or on a weight loss journey, or being bullied for their size?VirginiaOohhh… OK, so what would our terms be? They can't be the fat villain.CorinneWell, I feel like there's one list for anti fatness, and one would be a piece of culture or whatever that doesn't discuss dieting or weight loss. And I don't know if it should all be one under one Bechdel test umbrella, or if it should be two different tests.VirginiaI feel like it's related. Wait, I need to look up the actual Bechdel Test criteria.CorinneIt's like, does the movie have two female characters talking about something other than a man.VirginiaThe work must feature at least two women.They must talk to each other. And their conversation must be about something other than a man.I was just watching Your Friends and Neighbors, that new John Hamm show about super rich people stealing from each other, and it's very entertaining, but it fails the Bechdel test so dramatically. It's got Amanda Peet in it! She's so smart and funny, and all she does is talk about her ex husband and how much she loves him. And I'm just like, fail, fail, fail. Anyway, okay, I love this idea.CorinneSo it's like, does it have a fat character?VirginiaWait, I think it should have more than one fat character.CorinneThat bar is too high. I feel like we have to be able to name something that passes the test. And what are we calling the test? The Burnt Toast Test?VirginiaWe can workshop names in the comments.CorinneWe need a famous fat person to name it after, maybe.VirginiaWell, I guess Allison Bechdel named it after herself. So it could be the Fay test, because you did this. The Corinne Fay test.CorinneOh, God.So it has to have one fat character, they have to talk about something other than weight loss, and they can't be the villain.VirginiaI would like them not to be the sidekick, too. I think it's a central fat character.CorinneCan we name anything that passes?VirginiaShrill by Lindy West. And Too Much. Well, Lena Dunham doesn't totally pass the Bechdel Test, but she passes the fat test.CorinneSee, it gets very complicated. This is intersectionality!VirginiaWe strive for an intersectional world where the shows pass all the tests. This is such an interesting topic. I love this.CorinneI was also thinking about it because on my drive out, I read two of these Vera Stanhope mysteries. Have you read any of these?VirginiaI have not.CorinneThe main detective woman is fat, and I feel like it' mostly fine. Like, 90% of the time they're just talking about her, she's fat, and she's sloppy. She's a sloppy fat person. And then, like, occasionally, there'll be like, a sentence or two where I'm like, Ooh, I didn't like that.VirginiaIt's so deflating when you have something that's seeming good, and then it takes a turn on you real fast.CorinneSo would that pass the the fat Bechdel Test? Or whatever? Probably would.VirginiaBecause it's as good as we can get.CorinneShe's the main character and not talking about dieting, really.VirginiaYeah, wait, so where does it fall apart for you?CorinneI should have brought an example, but I feel like occasionally there will be narration about her, and it's suddenly like, “her body was disgusting,” you know? VirginiaOh God! I was thinking she maybe lumbered, or she sat heavily, or something. And you're like—CorinneYes. She sat heavily, that kind of thing. And I'm like, okay, sure.But occasionally there's just a twinge where I'm like, oh, you do kind of hate fat people.VirginiaI would then like that author to read Laura Lippman's work. Because Laura Lippman—regular Burnt Toasty! Hi, Laura!—has been doing such good work as a thin author to really work on her fat representation. And I just read Murder Takes a Vacation, which is one of Laura's most recent novels, and it's such a good read. Her protagonist, Mrs. Blossom, I believe was previously a side character in other novels who now has her own book. And the way she writes about body stuff in there is like… Laura's been doing the work. She's been really doing the work. It for sure, passes the Fay Fat Test.CorinneThat's awesome.VirginiaSo everyone check that out. And I would like Ann Cleeves to be reading Laura Lippman.Should we talk about airplanes? Are you in a safe space to talk about airplane feelings?CorinneSure. Yes.VirginiaCorinne was just quoted in The Washington Post, which is very exciting, alongside Tigress Osborne, friend of the show, Executive Director of NAAFA, about how Southwest Airlines is changing their passenger of size policy. Do you want to brief us on what's happening there?CorinneSo Southwest has had a policy in which a “customer of size,” meaning a person who doesn't fit between two plane arm rests, can book two seats and be refunded for the second seat. Or you could show up at the airport day of, and ask for two seats. And not have to pay up front and then be refunded.And in the past couple of months, this policy has somehow gotten really wobbly. I've heard all these anecdotal stories about people showing up at the airport and having Southwest tell them, “You're not going to be able to do this anymore.” Like, don't expect to show up and be able to book a second seat. You need to do it in advance. Blah, blah, blah.Now Southwest has come out and said they're changing the policy. They're also implementing assigned seating, which they didn't used to have. So going forward, you are going to have to book two seats in advance, and you will only be refunded if there are empty seats on the plane. Which, when are there ever empty seats?VirginiaThere are never empty seats on the plane? Never happens.I don't understand, because you needed two seats before, you still need two seats. So why does it matter whether there's an empty seat or not? My brain breaks trying to follow the logic.CorinneI think the logic says like they could have sold the second seat to someone else.VirginiaBut then they're not selling seats that work for people who are paying money to be there. Like, they're taking your money, but if you can't fit on the plane, then they just took your money. It's so shady,CorinneAnd people who don't need a whole seat don't pay less.VirginiaOver the age of two, your children do not get discounts for the fact that, they are using a third of a seat. You pay the same price for a child. CorinneYep. It's really sad, and it's making life harder and sadder for a lot of people.VirginiaI'm curious if another airline will step up on this. I think NAAFA has been doing a good job of making noise about this. I think people are putting pressure on them. It will be interesting if someone else realizes this is like a marketing opportunity.CorinneI think, they absolutely will not.VirginiaWell, I'm not naive enough to think someone would do it just because it's the right thing to do. But I'm hoping maybe one of Southwest's direct competitors would realize it's an opportunity.CorinneBut I think that Southwest previously was the that airline. I think they were using that to their advantage, and now I think they've just been like, “It's not worth it.” I think Alaska has the same policy where you can book two seats, and then if there is an empty seat, they'll refund it.VirginiaWell that's great because Alaska flies so many places, people need to go.CorinneWell, if you're in the if you're in the part of the country where I live, they do! But.VirginiaOh! That's good to know.CorinneI think they're more on a competition level with Southwest versus like United or something, right? I don't think United or Delta even has a customer of size policy.VirginiaThey've never cared.CorinneThere's no way to even book a second ticket for yourself, even if you want to just straight up pay for it.VirginiaIt leaves you the option of figuring out if you can afford business class to have a bigger seat. And that makes flying so much more expensive.CorinneRight? And it's also just like, does business class fit everyone? Probably not.VirginiaWell, we're mad about that, but I did, like seeing you in the Washington Post article saying smart things. So thank you. Thanks your advocacy.Let's see what else has been going on… The Guardian had this interesting piece, which I'm quoted in a little bit, by Andrea Javor. She's articulating something I've seen a few people starting to talk about, which is the experience of being on Ozempic and not losing weight from it.And I think this is an interesting kind of under the radar piece of the whole GLP1s discourse. Some folks are non-responders, whether because they stay on a lower dose by choice, and it improves their numbers, but they don't really lose weight, or some folks just don't really lose weight on it. Her piece really articulates her feelings of shame and failure that this thing that's supposed to be a silver bullet didn't work for her.CorinneWhen I started reading the piece, I was extremely confused, because the the author has diabetes, but type one diabetes, and these drugs don't help with type one diabetes. She eventually goes on it, just for weight loss. So what it didn't work for was weight loss, And I think it actually may have ended up helping with her, like A1C, and stuff. I agree that it does a good job of looking at the feelings that come along with that. And I do think, this does happen, and it's not being talked about as as much as it's happening probably.VirginiaIt feels important to highlight it in this moment where we have Serena Williams talking, about her husband's telehealth company and promoting her use of GLP1s. And we had a great chat on Substack chat about the whole Serena Williams of it all. So I won't rehash that whole discourse here. I also think that's a conversation where I want to hear from Black women. Chrissy King wrote an incredible piece. I also really appreciated the conversation that Sam Sanders, Zach Stafford and Saeed Jones had on Vibe Check about it. So, I don't need to get into Serena's personal choices. But it does mean, we have another huge, very admired celebrity pushing into the conversation again to say, “This is this magic trick. This is the thing I was always looking for. It finally worked for me” And we are all vulnerable to that messaging. So it's important to read stories like this one and understand oh, it really doesn't actually work for everybody. Setting aside whether we think people should be pursuing weight loss, this isn't necessarily going to be guaranteed, amazing results. CorinneAnother interesting article that I thought maybe would want to mention is the the one in The Cut about ARFID.VirginiaThis was a great cover story in New York Magazine. The headline is The Monster at the Dinner Table, and it's basically just encapsulating that ARFID has really been on the rise in recent years, and I think a lot of that is just because now we know what it is and we can diagnose it.But it did include a pretty interesting discussion of what causes kids to lose the instinct to eat, what things get in the way of it. Like, it can be trauma, it can be a feature of autism. It can be a choking experience, all sorts of different things.CorinneARFID is one of those conditions that I feel like I barely knew about before TikTok, and then I've just seen so much stuff about it on Tiktok.VirginiaIt only became a diagnosis in 2013, so it's very, very new. My kiddo would have been diagnosed with it, if it was more fully in the vernacular at that point, but it wasn't. So we were just told it was a “pediatric feeding disorder” type of thing. But it was very vague.I think it's great it's getting more attention. Both for kids and adults. It can be such a source of anxiety and shame for parents. It is so much work. It is very difficult, and it's harder than it should be because of diet culture, because of all the pressure put on parents to feed our kids certain ways. The backlash against ultraprocessed foods is really not helping anyone navigate ARFID. I can't underscore that enough, really not helping. No one needs to feel shame about your kid living on chicken nuggets or frozen burritos or whatever it is.CorinneThe amount of stigma against people who eat certain ways is nuts.VirginiaIt's nuts and it's sad.CorinneYeah it's socially isolating.VirginiaIt is harder to share, right? It's very socially isolating, and it's sad for the people around them. Anytime you're navigating eating together with someone with food restrictions, it does create barriers and extra work and more you have to navigate.But if we didn't have that layer of stigma over it, where it's like, it's probably the mom's fault, if only they like more whole foods at home, blah, blah, blah, blah, blah. Like, if we didn't have all of that, you could focus just on the logistics are hard enough. You don't need the shame.So many sad topics. Airlines are terrible. Virginia doesn't have any clothes to wear. ARFID is sad. Do we have anything to bring it up?CorinneWell, our exciting news? VirginiaOh, right! We are working on some very fun things.It is exciting to think about new directions that Burnt Toast and Big Undies are going in. So stay tuned. Don't worry, it's not a reality TV show.ButterVirginiaOkay, my Butter is adjacent to the wardrobe frustration conversation. Which is: I have started cutting the collars off a lot of my shirts.To back up: Last month, I'm on vacation in Cape Cod with my sister, and she comes down looking extremely cute. She's wearing a graphic tee tucked into a long maxi skirt. And I was like, “This whole thing is delightful. What's happening here?” And she was like, “Well, this shirt was actually too small for me, but I realized if I just cut the collar off it, it opened up the neck enough that then the shirt, the whole shirt fit better.” And she could still wear this cute shirt. And she said she got the idea from watching Somebody Somewhere, because Bridgett Everett cuts the collars off all her shirts.CorinneOh yes! That was my signature look when I was 18. A Hanes T-shirt with the collar cut off.VirginiaI'm dressing like 18-year-old Corinne, and I'm here for it! But I've realized, frequently a place that something doesn't fit me is my neck. I've talked about feelings about chins and necks. I have many complicated feelings about chins and necks. This is one place where my fatness sits. So the shirt might otherwise fit okay, but it doesn't fit my neck, and then it feels tight and it's a miserable feeling. So at the end of our trip, I wanted to buy a Cape Cod sweatshirt, because there were some really cute sweatshirts. But they were not size inclusive. So I was like, can I make this extra large work? And it was a little small, but I cut the collar off, and now it's okay.And then I did it with my old Harris Walz T-shirt from the election. It was a cute stripe. I just really liked the stripe. And I was like, Oh, I could still wear this if I get the collar off it. And a couple other things. I've just been, like, cutting collars off shirts that are uncomfortable. I'm into it!CorinneI think that's a great Butter. I'm into any kind of clothes modification that will make you wear stuff that you wouldn't otherwise wear.VirginiaIt was a good solution for a couple of things in my closet that I did like, but I was not reaching for. And now I'll use them again. And the key I figured out, because I experimented with a couple ways to cut it, is really just cut right along the seam of the sewed on collar. You might think that's going to not open it up enough, but it will stretch once you start wearing it. you could always cut more if you needed to, but that seems to have done it for me.CorinneOkay, well, I want to recommend a recipe, and I feel like I possibly mentioned this before. I'm staying with my mom, and we've been making this recipe from the New York Times called stuffed zucchini, and it's a really good recipe for if you have a surplus of zucchini, which a lot of people do this time of year. You kind of scoop out the middle of a zucchini and then mix some of that together with, like, sausage, tomatoes, basil, and then put it back in the zucchini and bake it with, like, some crispy breadcrumbs, and it's so good. I can literally, eat a whole zucchini in one sitting. Highly recommend.VirginiaThat sounds amazing. All right. Well, that makes me a little more excited about the season.CorinneYeah, it is a very good time of year for eating. We should have talked more about food maybe?VirginiaThat is a good point. Our tomatoes in the garden are going gangbusters. I've made some great sauces. I'm having a lot of cheese and tomato sandwiches. toasted and not toasted. Delightful.Well, this was a good family meeting catch up. I think we've covered a lot of ground. I'm excited to hear what folks are feeling about their dressing issues, and airlines, all the stuff we got into today.The Burnt Toast Podcast is produced and hosted by Virginia Sole-Smith (follow me on Instagram) and Corinne Fay, who runs @SellTradePlus, and Big Undies—subscribe for 20% off!The Burnt Toast logo is by Deanna Lowe.Our theme music is by Farideh.Tommy Harron is our audio engineer.Thanks for listening and for supporting anti-diet, body liberation journalism!. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit virginiasolesmith.substack.com/subscribe

Send us a textOn this episode of the Concrete Genius Podcast, Sauce McKenzie opens up about losing his cousin Denise and what that loss means for family, love, and perspective. He shares raw lessons on:Grieving while carrying the weight of leadership as a Black manThe importance of men's health: prostate checks, colon exams, blood pressure, A1C & disciplineThe prison system and why accountability matters more than excusesBreaking cycles of violence, ignorance, and community neglectThe need for self-love, self-respect, and unity in the Black communityThis episode is part memorial, part motivation, and seven minutes of game stretched into a whole lot of truth.

Prediabetes isn't just one thing, yet that's how it's usually treated. In this episode, Dr. Jedha unpacks the groundbreaking concept of prediabetes phenotypes, or “types,” showing how your body's unique pattern of blood sugar changes can reveal the real reasons behind your numbers.You'll learn about the four main types of prediabetes, whether your fasting glucose is high, your blood sugar spikes after meals, both are elevated, or your A1c is creeping up despite normal spot checks. More importantly, you'll discover what these patterns mean, and how pinpointing your type could unlock smarter, more personalized strategies to reverse the trend toward type 2 diabetes.This is a must-listen if you've ever felt stuck, frustrated, or confused by your lab results. You'll walk away with more clarity and confidence to take targeted steps to change your prediabetes health, because once you know your type, you can finally focus on what your body truly needs.For show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

Amelia Wood is an ACE-certified Personal Trainer dedicated to helping people feel strong, confident, and capable in their own bodies. Known for her approachable, no-gimmicks style, Amelia focuses on building sustainable fitness habits that fit real life. She's passionate about functional strength, movement that feels good, and empowering others to discover just how resilient they can be. In this episode, Dr. Brian, Dr. Tro, and Amelia talk about… (00:00) Intro (04:04) Why Amelia started her podcast, The Magic of Metabolic Health, and became a personal trainer (13:42) Learning delayed gratification and sustainably healthy living (18:06) Learning to enjoy exercise (25:04) Looking for the ‘why' behind behaviors you want to change (30:56) The five stages of achieving success (35:18) Cultural considerations when building a sustainably healthy lifestyle (47:39) Merging acting, entertainment, and wellness (51:24) What it means to be a ‘food first' personal trainer (and why CGMs are awesome!) (01:06:53) Gut health and overall metabolic health (01:11:50) A1C, fat, and butyrate (01:18:32) Outro For more information, please see the links below. Thank you for listening!   Links:   Please consider supporting us on Patreon: https://www.lowcarbmd.com/   Resources Mentioned in this Episode: Food Addiction Reset: https://www.foodaddictionreset.com Nutrition Network: https://nutrition-network.org Tro on Amelia's Podcast: https://www.youtube.com/watch?v=hQQkpHmwIdE   Amelia Wood: IG: https://www.instagram.com/primitivepulsefitness/ Website: https://www.primitivepulsefitness.com Podcast: https://www.youtube.com/@themagicofmetabolichealth The Great Surprisal: https://www.instagram.com/thegreatsurprisal/?hl=en   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/ 

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this solo episode,I dive deep into one of the most debated topics in diabetes care: A1C versus Time in Range—and why both still fall short without focusing on what I call Diabetes Stability.I shares my perspective on why A1C alone doesn't tell the whole story, how time in range can (and should) be customized to your needs, and why identifying your personal target number instead of target range matters more than just hitting Time In Range. Most importantly, I explain how living in alignment with the Five Pillars of Diabetes Success—mental health, strategic dosing, consistency & routines, nutrition, and physical well-being—creates long-term stability and reduces the burden of diabetes burnout.This episode is packed with practical insights and encouragement for anyone striving to feel more confident and in control of their diabetes.

Part 2 of Eoin's chat with Jason Ziobrowski (Chef Jay Z).Today's guest brings flavor, passion, and purpose to everything he does. Jason Ziobrowski — or as many know him, Chef Jay-Z — has spent nearly two decades as a corporate R&D chef, creating recipes and nutrition programs for hospitals, patients, and communities. His mission? To influence people positively through food and to help change the American palate, one dish at a time.But behind the chef's coat is a deeply personal journey. After years of being told he was simply ‘pre-diabetic,' Jason was finally diagnosed in 2020 with type 1.5 diabetes. At the time, his fasting sugars were nearly 22.2mmol/L (400mg/dL), and his A1C hit 14.Instead of giving up, Jason took charge. He overhauled his lifestyle cold turkey, dropping his fasting sugars down into a healthy range and transforming not just his health, but his outlook on life.Today, Chef Jay-Z is thriving with type 1, using technology like the Medtronic pump, leaning on his family, and continuing to inspire others through food, education, and his own story of resilience. From hospital kitchens to his own blood sugar battles, Jason has learned that lifestyle change isn't just necessary — it can be one of the best things to ever happen to you.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

In today's episode Eoin chats with Jason Ziobrowski (Chef Jay Z).Today's guest brings flavor, passion, and purpose to everything he does. Jason Ziobrowski — or as many know him, Chef Jay-Z — has spent nearly two decades as a corporate R&D chef, creating recipes and nutrition programs for hospitals, patients, and communities. His mission? To influence people positively through food and to help change the American palate, one dish at a time.But behind the chef's coat is a deeply personal journey. After years of being told he was simply ‘pre-diabetic,' Jason was finally diagnosed in 2020 with type 1.5 diabetes. At the time, his fasting sugars were nearly 22.2mmol/L (400mg/dL), and his A1C hit 14.Instead of giving up, Jason took charge. He overhauled his lifestyle cold turkey, dropping his fasting sugars down into a healthy range and transforming not just his health, but his outlook on life.Today, Chef Jay-Z is thriving with type 1, using technology like the Medtronic pump, leaning on his family, and continuing to inspire others through food, education, and his own story of resilience. From hospital kitchens to his own blood sugar battles, Jason has learned that lifestyle change isn't just necessary — it can be one of the best things to ever happen to you.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

What if the first signs of insulin resistance have nothing to do with glucose?In this episode of ReInvent Healthcare, Dr. Ritamarie uncovers the hidden metabolic dialogue between the liver and pancreas. It's a connection that begins to break down long before glucose or A1C raise red flags. Beneath the surface of “normal labs” lies a growing storm: insulin buildup, glucagon misfires, and early beta-cell stress that quietly unravel metabolic balance.If you're only testing blood sugar, you're missing the real story.Discover the overlooked markers that reveal the dysfunction most practitioners miss. This episode will change the way you view insulin resistance and give you the tools to catch it before the spiral begins.What's Inside This Episode?What most practitioners miss by focusing only on glucose, A1C, or symptomsHow to spot early-stage metabolic collapse while there's still time to reverse itWhy blood sugar may be the last thing to change and what starts breaking down long beforeThe overlooked conversation between two metabolic powerhouses and what happens when it goes quietHow hidden hormone signals spark a chain reaction of dysfunction no one's talking aboutThe surprising reason some clients wake up with high glucose even on a “perfect” dietClues your clients are missing the mark, not because of willpower, but because of broken feedback loopsResources and Links:Download our FREE Glucagon, Insulin, and Blood Sugar chart. Download our FREE Proinsulin, Insulin, and C-Peptide ChartJoin the Next-Level Health Practitioner Facebook group here for free resources and community supportReserve your spot for The REINVENT HEALTHCARE Intensive Learn Proven,​​ Leading-Edge Frameworks to Enhance Clinical Skills, Improve Visit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results. Check out other podcast episodes hereWhat's Inside This Episode?A conversation your client's blood sugar is already having—between liver, pancreas, insulin, and glucoseWhy fatty liver disrupts insulin clearance and leads to silent hyperinsulinemiaThe glucagon paradox: how this “forgotten hormone” can drive glucose production even in the fed stateBeta-cell stress decoded: how proinsulin and C-peptide ratios uncover hidden dysfunctionThe truth about "normal" A1C—and why it may just mean the pancreas is compensatingWhat poor insulin clearance looks like—and how to spot liver stress using routine labsHow and when to use labs like proinsulin, fasting glucagon, and FIB-4Natural strategies to restore liver-pancreas harmony with fasting, circadian alignment, and targeted nutrients

***JOIN THE NEXT MASTER YOUR FASTING CHALLENGE THAT STARTS October 1st, 2025!*** We'll GUIDE you on how to FAST to LOSE FAT for good, and use ‘fast cycling' to achieve uncommon results! ⁠REGISTER HERE!⁠ Click the link for DATES, DETAILS, and FAQs! This episode examines a critical 2025 systematic review and meta-analysis of 12 randomized controlled trials involving 966 type 2 diabetic participants, revealing a sobering truth about intermittent fasting: while it produces remarkable short-term benefits, these gains completely disappear after discontinuation. Dr. Scott and Tommy analyze how various fasting protocols (time-restricted eating, fast-mimicking diets, periodic fasting) significantly reduced A1C levels, fasting blood glucose, and body weight in under three months - but all parameters returned to pre-intervention levels within three months of stopping. This research powerfully illustrates why fasting must be approached as a permanent lifestyle change rather than a temporary diet solution. The hosts address the staggering diabetes epidemic: 38 million diagnosed Americans, 9 million undiagnosed, and 98 million with prediabetes - totaling 145 million Americans on the diabetes spectrum. Learn why the "rebound effect" occurs when fasting habits aren't sustained, and discover practical strategies for long-term adherence through personal anecdotes about adapting fasting to real-life situations like family dinners and social pressures. The episode introduces the concept of "momentary maintenance" - deliberate pauses in fat loss to build confidence in weight control rather than viewing plateaus as failures. This research validates that consistency trumps perfection, emphasizing that intermittent fasting works brilliantly when maintained but requires the same ongoing commitment as any other health practice to preserve its metabolic benefits. ⁠⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠⁠⁠⁠⁠⁠ Resources and Downloads: ⁠⁠⁠⁠⁠⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠⁠⁠⁠⁠⁠ Partner Links: Get your⁠⁠⁠⁠⁠⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠⁠⁠⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠⁠⁠⁠⁠⁠ here!⁠⁠⁠⁠⁠⁠⁠⁠ Get ⁠⁠⁠⁠⁠⁠⁠⁠25% off a Keto-Mojo⁠⁠⁠⁠⁠⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠⁠⁠⁠⁠⁠Click here!⁠⁠⁠⁠⁠⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠⁠⁠⁠⁠⁠Fasting For Life Community⁠⁠⁠⁠⁠⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links:⁠ https://www.sciencedirect.com/science/article/pii/S0271531725000600?via%3Dihub

Beverly Spring shares her powerful journey from chronic migraines and type 2 diabetes to improved health through faith-centered wellness. She discovers how integrating spiritual practices with nutrition and movement transformed her life despite multiple health challenges and family caregiving responsibilities.• Beverly suffered from chronic migraines since childhood but went "chronic" in the early 2000s• She discovered many of her migraine triggers were foods she naturally disliked—her body's innate intelligence protecting her• Medication for high cholesterol likely contributed to her type 2 diabetes diagnosis• Through Fast to Faith, Beverly reduced her A1C from 6.4 to 6.0, moving from diabetes to pre-diabetes range• She developed flashcards with scripture to replace negative self-talk with biblical truth• Simple stretching routines have significantly improved her neck and shoulder pain• Beverly completed the Fast to Faith coaching program despite undergoing shoulder surgery and caring for her husband after his double bypass• God's perfect timing allowed her own healing to progress enough to help her husband through his recoveryNever give up on your health journey—start where you are, even when circumstances aren't perfect. God cannot steer a parked car, so get into "messy action" and let Him direct your path.Women's Wellness Retreat at The Meadows on Rock Creek in beautiful Montana! Four days of faith-based wellness, hormone balance, clean living tips, and pure restoration—plus hiking, yoga, horseback riding, and gourmet meals in luxury cabins. Spots are limited, so grab your ticket today and let's do this together! https://themeadowsonrockcreek.com/special-events/womens-wellness-retreat/Thank you for listening to the Fast to Faith Podcast. Midlife Isn't a Crisis — It's Your Wake-Up Call Feeling stuck, restless, or like something's missing — even though you've checked all the boxes? It's not “just hormones,” and it's definitely not all in your head. The Midlife Reset Summit is here to help you uncover what's really holding you back — and give you the tools to break free. Join me and a powerhouse lineup of experts as we pull back the curtain on the hidden patterns, beliefs, and pressures that keep midlife women playing small. It's time to reclaim your energy, your clarity, and your confidence — and step fully into the next chapter with purpose.

We have a wonderful program in store for you this Saturday as The Word on Medicine brings you into the world of diabetes and specifically, Type 2 Diabetes - such an important topic in our society today. Dr. Michael (Mickey) Voss and Lisa Sherlock (RD, CDCES) will be joined by one of their patients in this fact-filled program. For those of you who are confused by A1C, insulin pumps, continuous glucose monitoring, and the difference between type 1 and type 2 diabetes, spend some time with The Word on Medicine, we will help you!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Dr. Vera Tarman sits down with Dr. Bart Kay—former professor of health sciences turned “nutrition science watchdog”—to unpack a big, practical question for people in recovery from ultra-processed food use: If sugar needs to go, what about other carbs? And where does dietary fat fit in? We explore Dr. Kay's perspective on the Randle (Randall) cycle, insulin resistance, mixed macro diets, seed oils, ketogenic/carnivore patterns, and real-world considerations for folks with sugar/UPF addiction who struggle to “moderate.” We also discuss staged change (don't flip your diet overnight), what “abstainer vs. moderator” can mean in food recovery, and how to keep any nutrition experiment aligned with your health team and your recovery plan. What we cover The “Randle cycle,” plain-English: why mixing higher carbs and higher fats may worsen metabolic friction, and why choosing one dominant fuel is central to Dr. Kay's model. Insulin resistance re-framed: why Dr. Kay views it as a protective cellular response (his position) and how that informs low-carb/carnivore advocacy. Carbs in recovery: “quit sugar” vs. “how low is low?”—Dr. Kay's thresholds (e.g., ≤50 g/day unlikely to cause problems in his view) and why many with UPF addiction do better with abstinence than moderation. Fats & satiety: why dietary fat often increases fullness cues; practical guardrails; “can you eat too much fat or protein?” Seed oils: Dr. Kay's strong critique of industrial seed oils and his inflammation concerns. Cholesterol worries on low-carb/carnivore: why lipid numbers may rise and how Dr. Kay interprets A1C and lipid changes (controversial; see note below). GLP-1s, metformin & meds: Dr. Kay's take on drug mechanisms vs. root-cause nutrition changes. Change management: why he recommends a 4–6 week ramp instead of an overnight switch to very low-carb/carnivore; supporting thyroid, energy, and the microbiome while you transition. Recovery lens: abstainer vs. moderator, harm-reduction steps when “only food will regulate,” and building a plan that supports mental health and addiction recovery. Key takeaways Abstinence can be a kindness. If you're a “can't moderate sugar” person, treating sugar/UPFs as an abstinence-worthy trigger can protect your recovery. Don't crash-diet your microbiome. If you're experimenting with lower-carb or carnivore, step down over 4–6 weeks with plenty of electrolytes, hydration, and support. Pick a lane with macros. In Dr. Kay's model, mixing higher carbs with higher fats is the most metabolically problematic; choosing one dominant fuel source may reduce friction. Numbers are data, not destiny. Lipids and A1C can shift on low-carb—interpret changes with a clinician who understands your whole picture (medical history, meds, symptoms, goals). Harm-reduction still counts. If full abstinence isn't feasible today: remove red-light foods first, shrink access, use “pause + plan” tools, and reach out before the binge. About our guest Dr. Bart Kay is a former professor of human physiology, nutrition, and vascular pathophysiology with teaching/research stints in New Zealand, Australia, the UK, and the US. He's consulted for elite sport and defense organizations and now educates the public on YouTube as a self-described nutrition myth-buster. One of his core topics is the Randle cycle and its implications for diet composition. Dr. Kay's YouTube: https://www.youtube.com/@Professor-Bart-Kay-Nutrition   The content of our show is educational only. It does not supplement or supersede your healthcare provider's professional relationship and direction. Always seek the advice of your physician or other qualified mental health providers with any questions you may have regarding a medical condition, substance use disorder, or mental health concern.

Episode 25:37 Here's 4 Ways To Lower Your A1C Level Naturally  More than 100 million Americans have elevated blood sugar levels… and don't even know it! Another 50 million have elevated levels and DO know it. That's not good! It's not good because elevated blood sugar levels lead to deadly sicknesses and diseases. Disease such as Obesity, Type 2 Diabetes, Heart Disease, Cancer, Alzheimer's and Dementia. So, how do you know if blood sugar levels are elevated? It's easy! Simply have your doctor order a blood test known as an “A1C Test.” If your A1C score is above 5.4 it's considered to be elevated (high).  It also places you at high risk for developing any of the diseases mentioned above. Fortunately, elevated levels of blood sugar… high A1C levels… can be reduced naturally, without drugs. On this episode I discuss four specific tactics for doing just that. Four lifestyle habits that you can begin to implement immediately that will help reduce your blood sugar levels and decrease your risk of developing a chronic disease.  Be sure to give this episode a good listen and, as always, share it with a friend. Thanks! ———————- Want to learn more? Continue the conversation regarding this episode, and all future episodes, by signing up for our daily emails. Simply visit: GetHealthyAlabama.com  Once there, download the “Symptom Survey” and you will automatically added to our email list. ———————- Also, if you haven't already, we'd appreciate it if you'd subscribe to the podcast, leave a comment and give us a rating. (Thanks!!!)  

               * This podcast is for informational and educational purposes only. It is not intended to diagnose or treat any disease. Please consult with your health care provider before making any health-related changes.

Christian holds a B.S. in Nutrition & Dietetics (Clemson), a Master's in Kinesiology (Cal State Fullerton, biomolecular exercise phys lab), is a CF-L1 since 2017, and was mentored by Dr. Andy Galpin. He's the founder of Sherpa Frontier, a physiology-first coaching company for elite athletes and high performers.What we cover (fast, actionable, no fluff):-Physiology-First: Why principles beat methods and how to pull the right levers (nutrition, sleep, training, blood sugar, recovery).-Blood Work That Actually Matters: Hidden markers (MCV, homocysteine, SHBG, A1C, CRP) that explain your plateau and what to do next.-Performance Fueling (No Fads): Carbs for output, macros that match training, and timing that kills crashes.-Recovery > Redlines: Readiness, HRV, and the “adaptation currency” mindset.-Coaching with a Blind Spot: How a legally blind coach developed elite-level cueing and communication.If you're done guessing and want measurable progress… this episode your blueprint.

***JOIN THE NEXT MASTER YOUR FASTING CHALLENGE THAT STARTS October 1st, 2025!*** We'll GUIDE you on how to FAST to LOSE FAT for good, and use ‘fast cycling' to achieve uncommon results! REGISTER HERE! Click the link for DATES, DETAILS, and FAQs! This episode examines a comprehensive narrative review analyzing fasting's profound effects on metabolic hormones and functions across 13 different studies and fasting protocols. Dr. Scott and Tommy reveal a game-changing mental approach: shift from counting down your fasting timer to counting up the powerful benefits accumulating in your body during each fast. The research demonstrates remarkable results from consistent intermittent fasting practices - 24-hour fasts performed three times weekly in women produced increased antioxidant activity, weight reduction, improved morning glucose levels, better A1C readings, and significant improvements in blood pressure, cholesterol, and triglycerides. Learn how 16:8 time-restricted eating for 12 weeks dramatically enhanced multiple metabolic markers in patients with metabolic syndrome, while understanding the crucial differences between fasting effects in lean individuals versus those with excess weight. The hosts clarify testosterone concerns, explaining why lean men may see temporary decreases with extended fasting protocols (typically due to inadvertent under-eating) while overweight men experience increases through improved testicular function and reduced estrogen conversion. Discover practical strategies for building sustainable fasting habits through progressive skill development rather than perfectionist approaches, including proper electrolyte management, leveraging gut microbiome improvements, and strategic meal planning for optimal fast-breaking. This episode reframes fasting as a learnable skill requiring practice and adaptation, providing specific guidance for developing your personal fasting toolkit based on your health status, body composition, and long-term metabolic optimization goals. ⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠⁠⁠⁠⁠ Resources and Downloads: ⁠⁠⁠⁠⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠⁠⁠⁠⁠ Partner Links: Get your⁠⁠⁠⁠⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠⁠⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠⁠⁠⁠⁠ here!⁠⁠⁠⁠⁠⁠⁠ Get ⁠⁠⁠⁠⁠⁠⁠25% off a Keto-Mojo⁠⁠⁠⁠⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠⁠⁠⁠⁠Click here!⁠⁠⁠⁠⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠⁠⁠⁠⁠Fasting For Life Community⁠⁠⁠⁠⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://pmc.ncbi.nlm.nih.gov/articles/PMC11560338/pdf/2188-2126-70-5-0348.pdf

Gestational diabetes (GDM) is one of the most common health issues during pregnancy, and diagnosing it is more complicated than you might think. In this episode, Dr. Dekker is joined by EBB Research Team member Dr. Morgan Richardson Cayama to cover the newly updated evidence on how GDM is diagnosed. They walk through the physiology behind GDM, current testing methods, and why there's still international disagreement about how to screen. Together, they examine the results of large randomized trials comparing the one-step and two-step screening methods, the research on early screening with hemoglobin A1C, and the evidence on alternatives to the Glucola drink, including candy and home blood sugar monitoring. They also review the risks of skipping screening entirely, and how weight bias and other systemic factors can impact diagnosis and care.   (02:28) What is Gestational Diabetes and Why Is It So Common? (06:30) Risk Factors, Size Bias, and the Role of Race and Ethnicity (10:40) Why We Screen and the Origins of the Controversy (13:17) Comparing the One-Step and Two-Step Methods (19:55) What New Research Says About Health Outcomes (23:45) Should We Screen for GDM Earlier in Pregnancy? (28:11) Can Hemoglobin A1C Replace the Glucola Drink? (32:44) Alternatives: Candy, Food, and Home Monitoring (40:04) What International Guidelines Recommend (43:07) Declining GDM Testing: What the Evidence Shows (47:47) Is Sperm Linked to Gestational Diabetes Risk? (51:29) Takeaways and the Future of GDM Diagnosis   Resources Download the free two-page handout in English or Spanish [NEED LINK] Explore Real Food for Gestational Diabetes by Lily Nichols: realfoodforgd.com For a full list of resources, visit ebbirth.com/inducinggdm For more information about Evidence Based Birth® and a crash course on evidence based care, visit www.ebbirth.com. Follow us on Instagram and YouTube! Ready to learn more? Grab an EBB Podcast Listening Guide or read Dr. Dekker's book, "Babies Are Not Pizzas: They're Born, Not Delivered!" If you want to get involved at EBB, join our Professional membership (scholarship options available) and get on the wait list for our EBB Instructor program. Find an EBB Instructor here, and click here to learn more about the EBB Childbirth Class.

What if the first signs of metabolic breakdown aren't in the pancreas or the blood sugar but hidden deep in the liver?In this episode of ReInvent Healthcare, Dr. Ritamarie takes you inside the metabolic feedback loop few practitioners are trained to detect. Long before glucose rises or A1C shifts, subtle signals in the liver may already be pointing to a much bigger problem. They're easy to miss, unless you know where to look. Discover the early biochemical whispers of insulin resistance, the hidden drivers of liver fat accumulation, and the lab markers most clinicians overlook. If your clients “look normal” on paper but still struggle, this is the episode you can't afford to skip.What's Inside This Episode?The silent organ shift that can signal metabolic trouble before blood sugar ever changesA hidden fat-making process your body might be running without your consentHow a sweet addiction quietly derails liver function and energy productionThe overlooked lab markers that whisper metabolic distress long before diagnosisA little-known score that could change how you assess “normal” labsSimple but strategic actions that tip the scales from fatty liver to functional healthHow small shifts in timing and nutrients may unlock powerful liver regenerationWhy stable glucose isn't the full story, and the signal you might be missingResources and Links:Download our FREE Metabolic Health Guide here. Here is a FIB-4 Calculator Tool FIB-4 = (Age × AST) / (Platelets × √ALT)NAFLD fibrosis score (NFS) = -1.675 + (0.037 × age) + (0.094 × BMI) + (1.13 × hyperglycemia) + (0.99 × AST/ALT ratio) - (0.013 × platelet count) - (0.66 × albumin)Join the Next-Level Health Practitioner Facebook group here for free resources and community supportVisit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results. Check out other podcast episodes here

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

In this episode, I'm joined by Carly Piehl, a 35-year-old mom and wife who was diagnosed with type 1 diabetes in late 2024 while in DKA, with no family history and no warning signs. Carley opens up about what those first overwhelming months were really like, from being sent home from the ER with a 13 A1C to navigating both the emotional and blood sugar rollercoaster. Despite early progress, she still felt stuck and frustrated until she found our signature group coaching program and discovered a new way to live with T1D. We talk about what it looks like to build confidence with food, technology, and mindset, especially while managing the daily demands of motherhood and marriage + the secret to her FIVE POINT A1C DROP. This episode is dedicated to anyone out there who has ever thought: Will I ever make peace with T1D? Quick Takeaways: The #1 thing that helped Carley make this transformation of lowering A1C from 13 to below 8.0 How to build confidence with food, technology, and mindset–especially while managing the daily demands of motherhood and marriage Advice AND treatment everyone should receive at diagnosis“That's when I realized, I was going to need to find other people who had diabetes to learn…”

In this episode, we shine a spotlight on insulin—an often overlooked but crucial hormone that plays a central role in metabolism and overall health. While blood sugar gets a lot of attention, insulin is the key regulator behind it, influencing energy storage, fat metabolism, and cellular function. We explore how insulin resistance develops, the early signs to watch for, and why it's so important to address this root issue to prevent chronic disease. We also discuss how ketogenic and low-carb diets can help regulate insulin levels, improve metabolic flexibility, and support weight management. This episode provides clear, functional insights into insulin's role and practical strategies for balancing it through nutrition and lifestyle, making it a must-listen for anyone interested in metabolic health and disease prevention. Also in this episode:  Keto Reset Program - Enrollment opens 8/28! Episode 76 Getting to the root of insulin resistance What is insulin and why does it matter? What is insulin resistance? What causes insulin resistance? How does it develop on a cellular level?  What are signs and symptoms of insulin resistance? How do we test for insulin resistance? Fasting insulin

Episode 25:34 Knowing Your INSULIN Level Is As Important As Knowing Your Blood Sugar Level. Here's Why…   Most doctors, when ordering blood work for a patient, will include an A1C test. This is wise because an A1C test will reveal what a person's blood sugar has been, on average, over the previous three months. Ideally, your A1C score should be below 5.7 (my preference is for it to be 5.4 or less). A score between 5.7 and 6.4 reflects Prediabetes, while a score of 6.5 or above is considered to be Diabetic. But there's a problem with this: A person's A1C score is NOT the only indicator of blood sugar issues. Or, stated another way, a person can have a normal A1C score and still have SEVERE blood sugar issues. How? By having elevated Insulin levels! On this episode I share the story of a patient of mine whose blood sugar levels were okay… but his Insulin levels were through the roof! In fact, his Insulin levels were so high that he was, in my opinion, a walking time bomb. However, because he had his Insulin levels tested… something MOST doctors don't do… we were able to identify this problem and address it accordingly. Be sure to give this episode a good listen as understanding the role of Insulin, and the importance of having it tested, is critically important for anyone who cares about their health.  And, as always, please share it with a friend. Thanks!  ———————- Want to learn more? Continue the conversation regarding this episode, and all future episodes, by signing up for our daily emails. Simply visit: GetHealthyAlabama.com  Once there, download the “Symptom Survey” and you will automatically added to our email list. ———————- Also, if you haven't already, we'd appreciate it if you'd subscribe to the podcast, leave a comment and give us a rating. (Thanks!!!)  

           * This podcast is for informational and educational purposes only. It is not intended to diagnose or treat any disease. Please consult with your health care provider before making any health-related changes.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684